CHRS
CHRS
NASDAQ · Biotechnology

Coherus Oncology Inc

$1.40
-0.05 (-3.45%)
As of Jun 30, 10:21 PM ET ·
Financial Highlights (FY 2026)
Revenue
53.72M
Net Income
214.01M
Gross Margin
67.2%
Profit Margin
398.4%
Rev Growth
-41.5%
D/E Ratio
0.84
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.2% 67.2% 57.2% 57.2%
Operating Margin -429.5% -386.6% -23.8% -20.0%
Profit Margin 398.4% 378.5% -24.2% -22.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 53.72M 91.87M 45.49M 44.34M
Gross Profit 36.12M 61.77M 26.00M 25.35M
Operating Income -230,712,426 -355,124,308 -10,840,195 -8,888,953
Net Income 214.01M 329.42M -11,017,037 -10,122,519
Gross Margin 67.2% 67.2% 57.2% 57.2%
Operating Margin -429.5% -386.6% -23.8% -20.0%
Profit Margin 398.4% 378.5% -24.2% -22.8%
Rev Growth -41.5% -41.5% +9.2% +11.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 52.02M 52.02M 52.40M 52.30M
Total Equity 62.13M 62.13M 72.90M 71.12M
D/E Ratio 0.84 0.84 0.72 0.74
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -225,723,474 -366,747,563 -13,211,435 -14,610,213
Free Cash Flow -11,236,120 -8,740,023